On this episode of the Real Life Pharmacology Podcast, I cover ziprasidone pharmacology. Ziprasidone has dopamine blocking activity and is classified as a second generation antipsychotic. Ziprasidone tends to have lower metabolic syndrome risks compared to other antipsychotics like clozapine and olanzapine. QTc prolongation is a significant risk with ziprasidone and be aware of drug interactions and electrolyte imbalances that may increase this risk.